1025 related articles for article (PubMed ID: 7794075)
1. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma.
Bhatavdekar JM; Patel DD; Ghosh N; Chikhlikar PR; Trivedi TI; Suthar TP; Doctor SS; Shah NG; Balar DB
Dis Colon Rectum; 1997 Jul; 40(7):785-90. PubMed ID: 9221853
[TBL] [Abstract][Full Text] [Related]
3. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
Pich A; Margaria E; Chiusa L
J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
[TBL] [Abstract][Full Text] [Related]
4. Ionizing radiation induces alterations in cellular proliferation and c-myc, c-jun and c-fos protein expression in breast epithelial cells.
Calaf GM; Hei TK
Int J Oncol; 2004 Dec; 25(6):1859-66. PubMed ID: 15547727
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa.
Visca P; Alò PL; Del Nonno F; Botti C; Trombetta G; Marandino F; Filippi S; Di Tondo U; Donnorso RP
Clin Cancer Res; 1999 Dec; 5(12):4111-8. PubMed ID: 10632348
[TBL] [Abstract][Full Text] [Related]
6. Value of glutathione S-transferase pi and the oncogene products c-Jun, c-Fos, c-H-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas.
Yokoyama Y; Sagara M; Sato S; Saito Y
Gynecol Oncol; 1998 Mar; 68(3):280-7. PubMed ID: 9570981
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
8. Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
Volm M; Mattern J
Anticancer Res; 1993; 13(6A):2021-5. PubMed ID: 8297109
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-erbB-2, p53 and c-myc proteins in male breast carcinoma: Comparison with traditional prognostic factors and survival.
Mourão Netto M; Logullo AF; Nonogaki S; Brentani RR; Brentani MM
Braz J Med Biol Res; 2001 Jul; 34(7):887-94. PubMed ID: 11449307
[TBL] [Abstract][Full Text] [Related]
10. Expression of cellular oncogenes in human gastric carcinoma: c-myc, c-erb B2, and c-Ha-ras.
Kim YJ; Ghu HD; Kim DY; Kim HJ; Kim SK; Park CS
J Surg Oncol; 1993 Nov; 54(3):167-70. PubMed ID: 8412172
[TBL] [Abstract][Full Text] [Related]
11. Gene expression in skin tumors induced in hairless mice by chronic exposure to ultraviolet B irradiation.
Sato H; Suzuki JS; Tanaka M; Ogiso M; Tohyama C; Kobayashi S
Photochem Photobiol; 1997 May; 65(5):908-14. PubMed ID: 9155265
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis.
Vora HH; Shah NG; Patel DD; Trivedi TI; Chikhlikar PR
J Surg Oncol; 2003 Jan; 82(1):34-50. PubMed ID: 12501167
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
[TBL] [Abstract][Full Text] [Related]
14. Abnormal expression of four novel molecular markers represents a highly aggressive phenotype in breast cancer. Immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein.
Han S; Yun IJ; Noh DY; Choe KJ; Song SY; Chi JG
J Surg Oncol; 1997 May; 65(1):22-7. PubMed ID: 9179263
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer.
Sanz-Ortega J; Steinberg SM; Moro E; Saez M; Lopez JA; Sierra E; Sanz-Esponera J; Merino MJ
Histol Histopathol; 2000 Apr; 15(2):455-62. PubMed ID: 10809364
[TBL] [Abstract][Full Text] [Related]
16. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
18. Association of genetic alterations of c-myc, c-fos, and c-Ha-ras proto-oncogenes in colorectal tumors. Frequency and clinical significance.
Nagai MA; Habr-Gama A; Oshima CT; Brentani MM
Dis Colon Rectum; 1992 May; 35(5):444-51. PubMed ID: 1373678
[TBL] [Abstract][Full Text] [Related]
19. A paradigm for oncogene complementation in human breast cancer.
Roux-Dosseto M; Martin PM
Res Virol; 1989; 140(6):571-91. PubMed ID: 2694252
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
